These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7934144)

  • 1. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
    Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
    Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
    Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
    Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts.
    Pallis M; Turzanski J; Langabeer S; Russell NH
    Adv Exp Med Biol; 1999; 457():77-88. PubMed ID: 10500783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML.
    Elgie AW; Sargent JM; Williamson CJ; Lewandowicz GM; Taylor CG
    Adv Exp Med Biol; 1999; 457():29-33. PubMed ID: 10500777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukaemia.
    Sincock PM; Ashman LK
    Leukemia; 1997 Nov; 11(11):1850-7. PubMed ID: 9369417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
    Jiang XR; Kelsey SM; Wu YL; Newland AC
    Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
    Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.
    Smeets ME; Raymakers RA; Vierwinden G; Pennings AH; Wessels H; de Witte T
    Blood; 1999 Oct; 94(7):2414-23. PubMed ID: 10498614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
    Linenberger ML; Hong T; Flowers D; Sievers EL; Gooley TA; Bennett JM; Berger MS; Leopold LH; Appelbaum FR; Bernstein ID
    Blood; 2001 Aug; 98(4):988-94. PubMed ID: 11493443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro study of blast cell metabolism in acute myeloid leukaemia using the MTT assay.
    Elgie AW; Sargent JM; Taylor CG; Williamson C
    Leuk Res; 1996 May; 20(5):407-13. PubMed ID: 8683980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
    Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
    Leuk Res; 2003 Feb; 27(2):183-91. PubMed ID: 12526924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
    Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin.
    Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
    Haematologica; 2000 Feb; 85(2):124-32. PubMed ID: 10681718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
    Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
    Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group.
    Paietta E; Andersen J; Racevskis J; Ashigbi M; Cassileth P; Wiernik PH
    Blood Rev; 1995 Mar; 9(1):47-52. PubMed ID: 7540903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhodamine 123-efflux from hematopoietic subpopulations and leukaemic blast populations marked by PerCP-conjugated monoclonal antibodies.
    Beck J; Gekeler V; Ringger M; Handgretinger R; Niethammer D
    Cancer Lett; 1996 Feb; 99(2):197-207. PubMed ID: 8616825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
    Marcelletti JF; Sikic BI; Cripe LD; Paietta E
    Cytometry B Clin Cytom; 2019 Jan; 96(1):57-66. PubMed ID: 30334334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.